We at sterna biologicals aim to causatively interfere at a very early stage with central type 2 inflammatory disease-causing mechanisms leveraging DNAazyme technology, a special type of antisense molecules. Our lead DNAzyme in clinical development possesses unique advantages compared to existing forms of therapy and seeks to provide medical relief to so far inadequately addressed patient populations suffering from type 2-driven inflammatory diseases.
For example SB010, one of our two lead programs for moderate and severe type 2-driven asthma, represents the result of a decade of research into DNAzymes and immunology. A range of publications in some of the world`s leading medical journals demonstrate that the master transcription factor GATA-3 of the Th2 pathway occupies a key position in the pathology of asthma. We discovered that the our GATA-3 specific lead molecule proved superior to other GATA-3 inhibitors in vitro and showed significant anti-inflammatory activities in pre-clinical models in vivo as well as later on also in Phase I and Phase IIa clinical trials.
Moreover, the characteristics of DNAzymes in general such as high specificity (i.e. very limited off-target effects), gymnotic delivery (i.e. no chemical modification and/or transfection reagents required for intracellular delivery), direct mRNA degradation, continuous enzymatic activity (i.e. one DNAzyme can cleave many mRNAs), fully synthetic manufacturing (i.e. highly economical production process), local administration (i.e. no systemic side effects), and a highly favorably safety/efficacy profile make them ideal drug candidates for us.